Nano-X Imaging Ltd. is set to report its Q3 earnings with analysts expecting a loss of $0.16 per share and revenues of $5.38 million. The company is currently dealing with multiple class-action lawsuits alleging securities law violations, which adds legal pressure. Despite unprofitability indicated by a negative P/E ratio of -0.82, Nano-X shows financial stability with a low debt-to-equity ratio of 0.06 and a strong current ratio of 3.64. Investors will watch closely to see how these challenges impact the company's future performance.
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
